Enzolytics Inc (ENZC)

[falon]

The EVOLUTION of ENZC is not BULLSHIT!

It is all in BLACK and WHITE in the PRESS RELEASES.

What ENZC is trying to accomplish didnot happen overnight, it was well planned out and there have been setbacks and will be more setbachs however ENZC continues to press on.

The company was a mess FINANCIALLY.

They were behind in the reporting.

The had 100 of millions of shares in toxic financing.

Their Phase III trial for ITV-1 although successful has to be done again to get proper regulatory approval.

So what did they do?

It all started more than a year ago.

Here is where ENZC publicly stated THIS IS NOT FROM OUR COMPANY!!!

Enzolytics Comments on Recent Market Activity and Shareholder Update

DALLAS, TX / ACCESSWIRE / February 6, 2020 / Enzolytics- (OTC Pink Sheet-ENZC) was notified by FINRA that an unauthorized press release titled, "Enzolytics Inc., Launches Coronavirus Prevention Kit" was distributed to the public. Enzolytics and its management had no knowledge of this press release in any manner, and disavows any information contained in this press release. The company does not have a "Coronavirus Prevention Kit" and finds the claim reckless and fraudulent.

Enzolytics, Inc., Inc. is diligently working to bring its filings current and continue with its initiatives for the commercialization of its proprietary proteins for the treatment of HIV.

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets

- Open operation in the Dallas, Tx area where the company has relocated

- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.

- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.

- Further our development in North America of our Flagship HIV immune treatment compound IPF

PLANO, TX / ACCESSWIRE / September 16, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas.

The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/

This is an Analysis of what may become of ENZC.

Analysis:

ENZC is a penny stock and as with penny stock there is a high risk that one could lose most if not all of their investment. The possibility exist that all we have witness up-to date is one of the most intricate frauds in the history of the stock market.

Successful investing is about managing risk, not avoiding it

Benjamin Graham


ENZC is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.

Enzolytics' flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the SARS-CoV-2 Coronavirus.

ENZC is in a great position to disrupt the drug market for HIV, Coronavirus, Multiple Sclerosis and other diseases. They have been making great strides to accomplish this and much more progress is necessary to enable them to get their technology to the marketplace. They have been very forthcoming and keep shareholders abreast of certain developments as they move through the necessary processes to reach their intended results.

The beauty of ENZC is the 2 prong punch of the ITV-1 1 (Immune Therapeutic Vaccine-1), and Cl3hmAb (human monoclonal antibody) and the man in Charge, Chares S. Cotropia.

Mr. Cotropia appears to have a well-defined game plan that he has shared with shareholders through press releases and is evident as seen in the share price. The game plan seems to be working beautifully as he pointed out in the Press Release dated October 19, 2020:

All of our steps are taken with two objectives in mind.

First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus.

Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.


Now with the way the stock price is performing, objective one from the above paragraph is more likely to happen than not and objective two is already happening.